SCHEMBL6541516

SCHEMBL6541516

CC1Nc2cc(-c3ccc(Cl)cc3)ccc2NC1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRPF1 P55201 1/20 0.54
CREBBP Q92793 1/20 0.54
BRD4 O60885 1/20 0.50
PGR P06401 8/20 0.48
TSHR P16473 1/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 3/20 0.40
GSK3B P49841 2/20 0.40
JAK2 O60674 1/20 0.40
NTRK1 P04629 1/20 0.40
MET P08581 1/20 0.40
FGFR1 P11362 1/20 0.40
PRKACA P17612 1/20 0.40
KDR P35968 1/20 0.40
MAP2K2 P36507 1/20 0.40
FLT3 P36888 1/20 0.40
MAP2K1 Q02750 1/20 0.40
MST1R Q04912 1/20 0.40
NTRK3 Q16288 1/20 0.40
NTRK2 Q16620 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7170205 0.88 BRPF1 (0.59) BRPF1CREBBPBRD4PGRTSHR
SCHEMBL7171052 0.88 BRPF1 (0.59) BRPF1CREBBPBRD4PGRTSHR
SCHEMBL7175133 0.88 BRPF1 (0.59) BRPF1CREBBPBRD4PGRTSHR
SCHEMBL12597037 0.79 CREBBP (0.66) BRPF1CREBBPBRD4PGRALDH1A1
SCHEMBL16120451 0.75 BRPF1 (0.59) BRPF1CREBBPBRD4PGRTSHR
SCHEMBL6540662 0.75 BRPF1 (0.59) BRPF1CREBBPBRD4TSHRALDH1A1
SCHEMBL15823711 0.75 BRPF1 (0.59) BRPF1CREBBPBRD4TSHRALDH1A1
SCHEMBL4863718 0.75 BRPF1 (0.59) BRPF1CREBBPBRD4PGRTSHR
SCHEMBL7485845 0.74 TGM2 (0.53) BRPF1CREBBPPGRTSHRMEN1
SCHEMBL7672651 0.72 CREBBP (0.51) BRPF1CREBBPBRD4PGRTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6794373-B2 ADMINISTERING TO A FEMALE OF CHILD BEARING AGE OVER A PERIOD OF 28 CONSECUTIVE DAYS A FIRST PHASE OF FROM 18 TO 21 DAILY DOSAGE UNITS OF A PROGESTATIONAL AGENT, AND A SECOND PHASE OF FROM 1 TO 7 DAILY DOSAGE UNITS OF AN ANTIPROGESTIN AGENT WYETH 2004-09-21 US disclosed
US-20020151531-A1 Contraceptive methods using benzimidazolones LIGAND PHARMACEUTICALS INCORPORATED 2002-10-17 US disclosed
US-20020115853-A1 Benzimidazolones and analogues WYETH 2002-08-22 US disclosed
US-6423699-B1 CONTRACEPTIVES AMERICAN HOME PRODUCTS CORPORATION 2002-07-23 US disclosed
US-6380235-B1 USEFUL AS PROGESTERONE RECEPTOR AGONISTS AND ANTAGONISTS, USED FOR CONTRACEPTION, IN THERAPY OF FIBROIDS, ENDOMETRIOSIS, BREAST, UTERINE, OVARIAN AND PROSTATE CANCER, AND POST MENOPAUSAL HORMONE REPLACEMENT THERAPY AMERICAN HOME PRODUCTS CORPORATION 2002-04-30 US disclosed
EP-1173213-A1 COMPOSITIONS CONTAINING BENZIMIDAZOLONES AND PROGESTOGENS American Home Products Corporation (US) 2002-01-23 EP disclosed
EP-1173423-A1 BENZIMIDAZOLONES AND ANALOGUES AND THEIR USE AS PROGESTERONE RECEPTOR LIGANDS American Home Products Corporation (US) 2002-01-23 EP disclosed
WO-2000066564-A1 BENZIMIDAZOLONES AND ANALOGUES AND THEIR USE AS PROGESTERONE RECEPTOR LIGANDS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-11-09 WO disclosed
WO-2000066168-A1 COMPOSITIONS CONTAINING BENZIMIDAZOLONES AND PROGESTOGENS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151531-A1 Contraceptive methods using benzimidazolones PGR, GNRHR, NR4A1 BRPF1 569/4885CREBBP 2696/4885BRD4 114/4885
US-20020115853-A1 Benzimidazolones and analogues PGR, NR5A1, NR3C2 BRPF1 759/4885CREBBP 2373/4885BRD4 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.